Please use this identifier to cite or link to this item:
Title: A cautionary tale of the use of lenalidomide and dexamethasone for relapsed/refractory immunoglobulin light chain (AL) amyloidosis.
Epworth Authors: Prince, Miles
Keywords: Lenalidomide
Immunoglobulin Light Chain (AL) Amyloidosis
Predictors of Efficacy
RD Combination
Department of Haematology, Epworth HealthCare, Melbourne, Victoria, Australia
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Oct-2021
Publisher: Wiley Blackwell
Citation: Br J Haematol . 2021 Oct;195(2):160-161
Abstract: Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up. Basset M, Kimmich CR, Schreck N, Krzykalla J, Dittrich T, Veelken K, Goldschmidt H, Seckinger A, Hose D, Jauch A, Müller-Tidow C, Benner A, Hegenbart U, Schönland SO. Br J Haematol. 2021 Oct;195(2):230-243. doi: 10.1111/bjh.17685. Epub 2021 Aug 3. PMID: 34341985
DOI: 10.1111/bjh.17710
ISSN: 0007-1048
Journal Title: British Journal of Haematology
Type: Comments
Affiliated Organisations: Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.